NeoChord

NeoChord is a pioneering medical device company developing and commercializing a novel, minimally invasive solution for mitral valve repair. Its core technology, the DS1000 system, allows for transapical implantation of artificial chordae on a beating heart under echocardiographic guidance, offering a potential alternative to traditional open surgery or complex transcatheter approaches. The company is CE-marked and commercially active in Europe but remains in the investigational stage in the United States. With a seasoned board and a focus on a large cardiovascular market, NeoChord is positioned as a specialist in direct repair techniques.

The NeoChord Artificial Chordae Delivery System (DS1000) is a single-use device for transapical, off-pump, beating-heart implantation of artificial chordae under real-time 2D/3D echocardiographic guidance to treat mitral valve regurgitation.

NeoChord competes in the structural heart market dominated by large players like Abbott (MitraClip/TriClip) and Edwards Lifesciences (PASCAL) in transcatheter repair, as well as traditional surgical valve repair/replacement. It positions itself as a minimally invasive surgical alternative, focusing on direct anatomical repair for a specific patient subset, rather than a broad transcatheter solution.